Join a Legacy of Innovation 110 Years and Counting!
Daiichi Sankyo Group is dedicated to the creation and supply of innovative pharmaceutical therapies to improve standards of care and address diversified, unmet medical needs of people globally by leveraging our world-class science and technology. With more than 120 years of scientific expertise and a presence in more than 20 countries, Daiichi Sankyo and its 16,000 employees around the world draw upon a rich legacy of innovation and a robust pipeline of promising new medicines to help people. In addition to a strong portfolio of medicines for cardiovascular diseases, under the Group’s 2025 Vision to become a “Global Pharma Innovator with Competitive Advantage in Oncology,” Daiichi Sankyo is primarily focused on providing novel therapies in oncology, as well as other research areas centered around rare diseases and immune disorders.
Summary
This position will lead the valuation processes for in-licensing, out-licensing, co-development and/or acquiring opportunities. Accountable to own the financial evaluation model developed in close collaboration with Global Business Development (US, Japan, EU teams), Finance (Corporate FP&A & R&D), Global Commercial & Strategy, Global Forecasting & Insights and Global Project Management. Successful execution will involve working cross-functionally to gather relevant information, synthesize the materials, and develop comprehensive opportunity assessments consistent with our corporate business development strategy. This position may lead a small team and will report to the Head of Forecasting/Business Analytics and Deal Valuations.
Responsibilities
Cross-functional Collaboration:
- Collaborate with and lead cross functional teams (global/regional RD, IP, Legal, Finance, Forecasting, Manufacturing/Supply Chain, Commercial) to evaluate and execute on deal opportunities, including managing the interface with global/regional teams and ensuring alignment with project assumptions.
- Collaborate and set stage with the wider GBD team to formulate partnering strategy and objectives by providing insights and making recommendations with significant potential impact.
Deal Valuation NPV Modeling Financial Support:
- Provide independent and high-quality financial support to all BDL transactions including In-Licensing, Out-licensing, Collaborations, and other strategic business initiatives.
- Develop valuation model, including sourcing and validation of key assumptions and data from global cross-functional teams (Marketing, RD, Finance, Supply Chain, etc).
Deal Valuation Analysis:
- Lead analysis of financial analysis and models underpinning deal terms; analyze deal economics quickly to identify key value drivers and looks at key sensitivities. Preparation of financial aspects of business cases including valuation, PLs, cash flow analyses, sensitivity analyses, and other relevant financial metrics slides for presentation to governance committees.
- Orchestrate and drive detailed comparator deal analysis and run valuation scenarios to align proposed terms for new collaborations.
Post Deal Support Analysis:
- Post deal support to DS Tokyo External Auditors, including asset Impairment Test analysis (explain deal structure, rationale and source of assumptions and key data supporting the deal valuation model)
Qualifications: Successful candidates will be able to meet the qualifications below with or without a reasonable accommodation.
Education Qualifications (from an accredited college or university)
- Bachelor's Degree Concentration in Finance/Business/Accounting is preferred required
- MBA Top tiered business school is highly preferred
Experience Qualifications
- 10 or More Years Pharmaceutical/Biotech/Life Sciences/Investment Banking industries experience required
- 4 or More Years BD&L transactions financial modeling required
Travel
Ability to travel up to 20% Business meetings and/or conferences as required.
Daiichi Sankyo, Inc. is an equal opportunity/affirmative action employer. Qualified applicants will receive consideration for employment without regard to sex, gender identity, sexual orientation, race, color, religion, national origin, disability, protected veteran status, age, or any other characteristic protected by law.
What We Do
Daiichi Sankyo is dedicated to creating new modalities and innovative medicines by leveraging our world-class science and technology for our purpose “to contribute to the enrichment of quality of life around the world.” In addition to our current portfolio of medicines for cancer and cardiovascular disease, Daiichi Sankyo is primarily focused on developing novel therapies for people with cancer as well as other diseases with high unmet medical needs. With more than 100 years of scientific expertise and a presence in more than 20 countries, Daiichi Sankyo and its 16,000 employees around the world draw upon a rich legacy of innovation to realize our 2030 Vision to become an “Innovative Global Healthcare Company Contributing to the Sustainable Development of Society.” For more information, please visit www.daiichisankyo.com.
